Deep-pocketed investors have adopted a bullish approach towards Abbott Laboratories ABT, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in ABT usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for Abbott Laboratories. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 50% leaning bullish and 25% bearish. Among these notable options, 5 are puts, totaling $240,592, and 3 are calls, amounting to $244,878.
Expected Price Movements
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $105.0 to $130.0 for Abbott Laboratories over the recent three months.
Analyzing Volume & Open Interest
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Abbott Laboratories's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Abbott Laboratories's whale activity within a strike price range from $105.0 to $130.0 in the last 30 days.
Abbott Laboratories 30-Day Option Volume & Interest Snapshot
Biggest Options Spotted:
Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
---|---|---|---|---|---|---|---|---|---|---|---|
ABT | CALL | SWEEP | BULLISH | 11/15/24 | $8.8 | $8.65 | $8.8 | $105.00 | $160.1K | 382 | 182 |
ABT | PUT | TRADE | NEUTRAL | 08/16/24 | $19.1 | $18.6 | $18.87 | $125.00 | $94.3K | 3 | 50 |
ABT | CALL | SWEEP | BULLISH | 11/15/24 | $8.85 | $8.65 | $8.8 | $105.00 | $58.9K | 382 | 249 |
ABT | PUT | TRADE | BEARISH | 05/17/24 | $23.65 | $23.1 | $23.48 | $130.00 | $44.6K | 0 | 19 |
ABT | PUT | SWEEP | BULLISH | 05/17/24 | $1.05 | $1.02 | $1.02 | $106.00 | $38.2K | 218 | 679 |
About Abbott Laboratories
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Where Is Abbott Laboratories Standing Right Now?
- Currently trading with a volume of 4,096,535, the ABT's price is up by 0.3%, now at $106.29.
- RSI readings suggest the stock is currently may be approaching oversold.
- Anticipated earnings release is in 78 days.
What The Experts Say On Abbott Laboratories
A total of 4 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $129.5.
- An analyst from RBC Capital persists with their Outperform rating on Abbott Laboratories, maintaining a target price of $125.
- Maintaining their stance, an analyst from Barclays continues to hold a Overweight rating for Abbott Laboratories, targeting a price of $140.
- An analyst from Citigroup persists with their Buy rating on Abbott Laboratories, maintaining a target price of $128.
- An analyst from Evercore ISI Group has decided to maintain their Outperform rating on Abbott Laboratories, which currently sits at a price target of $125.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Abbott Laboratories, Benzinga Pro gives you real-time options trades alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.